mechanism of action of glp-1 receptor agonists Current Insights, Advantages and Challenges Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Frontiers | GLP-1 Receptor Agonists:

They are not for human consumption, medical treatment, diagnosis, or disease prevention

January 2026

GLP-1R regulation of food intake The reduction in body weight induced by GLP-1R agonists is largely attributed to a reduction in food intake

doi: 10.1056/NEJMoa1916038

FTC Lawsuit Against PBMs Moves Forward : A federal judge rejected an attempt to block the FTCs lawsuit against major PBMs, including Caremark, Express Scripts, and Optum Rx

As mentioned by Lingvay et al., semaglutide has shown promise as a treatment option for non-diabetics with established atherosclerotic disease by reducing their risk of MACE by 20% despite having varying HBA1c baselines [47]